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Preserved structural connectivity mediates the
clinical effect of thrombolysis in patients with
anterior-circulation stroke
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Keith W. Muir15, Norbert Nighoghossian16, Salvador Pedraza17, Josep Puig17, Claus Z. Simonsen18,
Vincent Thijs19,20, Anke Wouters12,13,14, Christian Gerloff1, Götz Thomalla1 & Bastian Cheng 1✉
Thrombolysis with recombinant tissue plasminogen activator in acute ischemic stroke aims
to restore compromised blood flow and prevent further neuronal damage. Despite the proven
clinical efficacy of this treatment, little is known about the short-term effects of systemic
thrombolysis on structural brain connectivity. In this secondary analysis of the WAKE-UP
trial, we used MRI-derived measures of infarct size and estimated structural network dis-
ruption to establish that thrombolysis is associated not only with less infarct growth, but also
with reduced loss of large-scale connectivity between grey-matter areas after stroke. In a
causal mediation analysis, infarct growth mediated a non-significant 8.3% (CI95% [−8.0,
32.6]%) of the clinical effect of thrombolysis on functional outcome. The proportion medi-
ated jointly through infarct growth and change of structural connectivity, especially in the
border zone around the infarct core, however, was as high as 33.4% (CI95% [8.8, 77.4]%).
Preservation of structural connectivity is thus an important determinant of treatment success
and favourable functional outcome in addition to lesion volume. It might, in the future, serve
as an imaging endpoint in clinical trials or as a target for therapeutic interventions.
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Systemic thrombolysis with recombinant tissue plasminogenactivator is an effective treatment for acute ischemicstroke1,2. Its beneficial effect on clinical outcome is com-
monly attributed to the attenuation of growth of irreversible
tissue damage after recanalization of an arterial occlusion.
However, it remains an open question which imaging biomarker
of preserved brain structure is most suited for explaining the
favorable effects of reperfusion and for making accurate predic-
tions of clinical outcome.
One common surrogate marker for tissue loss is the volume of
a stroke lesion as measured by restricted diffusion on magnetic
resonance imaging (MRI), or hypodensity or impaired perfusion
on computed tomography (CT). In the absence of reperfusion,
stroke lesions grow in the first hours and days after stroke
onset3–5 due to the conversion of areas with reversible ischemia to
infarction. Secondary analyses of large clinical trials indicate that
alteplase reduces lesion growth in short- and long-term follow-
ups ranging from 24 h to 3 months6–8. In a pooled analysis,
attenuation of lesion growth by thrombolytic therapy was asso-
ciated with favorable clinical outcome9–11. However, there are
exceptions to this general trend. In the recent DEFUSE-3 trial, the
clinical benefit of arterial recanalization was not accompanied by
large statistically significant differences of absolute lesion volumes
or growth between the treatment group and control group on
follow-up imaging 24 h after stroke12. A similar observation was
made in the WAKE-UP trial (Efficacy and Safety of MRI-Based
Thrombolysis in WAKE-UP Stroke). In WAKE-UP, patients with
unknown time of stroke onset were randomized to alteplase or
placebo based on an MRI selection criterion13. Treatment with
alteplase was effective in terms of a favorable clinical outcome
measured by a modified Rankin scale (mRS) score of 0–1 points.
While significantly higher rates of favorable outcome were
observed in the alteplase group, this was not associated with
smaller stroke lesion volumes 22–36 h after stroke compared to
placebo.
These findings indicate that factors other than the size of stroke
lesions may be relevant for the therapeutic effect of thrombolytic
therapy. In particular, lesion location determines neurological
deficits, and spatial patterns of lesion distribution are linked to
clinical outcome14. Furthermore, beyond focal damage, stroke
lesions impair neurological functions by disrupting the large-scale
spatiotemporal organization of neuronal activity in the brain15.
The physical substrate for this is the structural connectome,
representing anatomical connections in the brain. Stroke lesions
frequently occur in the cerebral white matter, disrupting essential
pathways of the structural connectome that support and shape
normal brain function16. These disruptions can be quantified
using graph-theoretical measures of large-scale network
topology17–19. Complementarily, structural disconnection can be
characterized by loss-of-connectivity profiles of pre-specified
cortical and subcortical grey-matter regions. The pattern and
extent of structural disconnections depend on the size and ana-
tomical localization of causative stroke lesions and determine the
nature of functional deficits20 and clinical recovery after stroke21
beyond measures of focal damage. The effects of systemic
thrombolysis on structural connectivity changes after stroke have
not yet been examined.
We aimed to investigate changes in the structural connectome
after thrombolysis using data from a large prospective, rando-
mized, multicentre trial of thrombolysis in acute ischemic stroke.
In this secondary analysis of the WAKE-UP trial (ClinicalTrials.
gov number NCT01525290, EudraCT number 2011-005906-32),
stroke lesions were projected onto reference tractograms from
healthy subjects to determine their effect on the structural con-
nectivity profile. We hypothesized that treatment with alteplase
would attenuate the loss of structural connectivity and that
preserved connectivity, in addition to reduced growth of the
ischemic lesion, would contribute to mediating the treatment
effect of systemic thrombolysis.
Results
Patient characteristics. The composition of the final study
population resulting from the application of inclusion and
exclusion criteria is shown in Supplementary Fig. 1. Of 503
patients randomized in the WAKE-UP trial to receive placebo or
alteplase, 352 had MR imaging data of acceptable quality both
before randomization and 22–36 h after stroke. Of those, 278
(79.0%) had an anterior-circulation stroke (territory supplied by
the anterior or middle cerebral artery; 160 lesions in the left
hemisphere, 109 lesions in the right hemisphere, 9 bilateral); 61
(17.3%) had a posterior-circulation stroke (25 PCA, 7 cerebellum,
29 brain stem) and 13 (3.7%) had signs of acute cerebral ischemia
in more than one vascular territory.
Of the 269 patients thus included in the study, 142 were
randomized to placebo and 127 to alteplase. Age (placebo: mean
66.0 ± 11.1 years; alteplase: mean 65.2 ± 11.3 years) was
comparable between the two groups, while baseline NIHSS scores
(placebo: median 7, interquartile range [4, 11]; alteplase: median
6, IQR [3.5, 8]) showed a tendency toward higher values in the
placebo group.
Median duration from pre-randomization MRI to follow-up
imaging was 26:03 h (IQR [24:22, 29:03] hours). Spatial
distribution of stroke lesions is shown in Supplementary Fig. 2.
Of the 151 patients excluded from analysis because of
insufficient image quality, 119 had anterior-circulation infarcts.
Their age (66.4 ± 11.7 years) and baseline NIHSS scores (median
6, IQR [4, 10.5]) were similar to the study population.
Treatment effects and clinical outcome. In 6 of 269 patients
(2.2%, 2 placebo, 4 alteplase), the primary endpoint was missing.
Of the remaining patients, 131 (49.8%) reached the primary
endpoint of modified Rankin scale score 0 or 1. This favorable
outcome was achieved in 58 patients in the placebo group (41.4%)
and in 73 patients in the alteplase group (59.3%). In a logistic
regression analysis, alteplase was associated with a higher prob-
ability of favorable clinical outcome (odds ratio [OR] adjusted for
age, baseline NIHSS score and pre-randomization lesion volume
1.98, 95%-confidence interval [CI95%] [1.13, 3.51], P= 0.018).
Stroke lesion volumes. In the study population, median lesion
volume on diffusion-weighted imaging (DWI) before randomi-
zation was 3.0 ml (IQR [1.0, 9.9] ml). After 22–36 h, median
lesion volumes, measured on FLAIR imaging, had increased to
4.4 ml ([1.4, 22] ml), which was significant in a Wilcoxon signed-
rank test (P < 2 × 10−16). In the placebo group, lesion volume
increased from 4.0 ml (IQR [1.3, 10] ml) to 5.5 ml (IQR [1.7, 25]
ml). In the thrombolysis group, infarcts grew from 2.2 ml (IQR
[0.87, 9.9] ml) to 3.4 ml (IQR [1.1, 20] ml) as illustrated in
Supplementary Fig. 3. Absolute lesion volumes did not differ
between placebo and alteplase groups before randomization (P=
0.139), but at follow-up were smaller in the thrombolysis group
(P= 0.044). Larger increases of infarct size were observed in the
placebo group (median 2.3 ml; IQR [0.24, 17] ml) compared to
patients treated with alteplase (median 1.0 ml; [−0.27, 7.5] ml).
The difference was statistically significant (Mann–Whitney U test,
two-sided P= 0.018). This interaction was confirmed in a linear-
mixed effects model of the temporal evolution of lesion volume as
well as in a simple linear regression of lesion volume at T2 against
treatment allocation with lesion volume at T1 included as a
nuisance regressor (Supplementary Table 1). Adjusted for age,
baseline NIHSS score, baseline lesion volume and treatment
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allocation, higher infarct growth was strongly associated with a
lower probability of achieving a favorable functional outcome:
the odds ratio associated with a doubling of the growth ratio
volT2/volT1 was 0.77 (CI95% [0.62, 0.93], P 0.009).
Systemic thrombolysis modifies the progression of network
disruption after stroke. Pattern and magnitude of network dis-
ruptions induced by the initial ischemic lesions, quantified by the
Change of Connectivity (ChaCo) score, are illustrated in Fig. 1. In
this score, values of zero indicate that reconstructed fiber bundles
originating from a grey-matter area do not pass through the
stroke region at all (no disconnection), while the maximal value
of one represents complete disconnection of a piece of cortex or
subcortical nucleus from the rest of the network.
The propensity of brain areas to be affected by any structural
disconnection was spatially highly heterogenous. While in only
35% of patients the frontal pole was involved, all subjects showed
at least some structural disconnection in the insular and
precentral cortices as well as the subcortical regions of the
caudate, pallidum, and putamen. Mixed effects logistic regression
models did not show a significant difference between treatment
groups for the propensity of brain regions to be affected by any
degree of disconnection (Supplementary Table 2).
The median magnitude of non-zero ChaCo scores was also
variable across brain regions, ranging from 1.43 × 10−05 (IQR
[4.74 × 10−06, 4.85 × 10−05]) in the cuneus to 0.085 (IQR [0.019,
0.246]) in the putamen. After applying a logarithmic transforma-
tion, visual inspection of their distributions did not indicate a
substantial deviation from the assumptions of conditional
normality and constant variance (Supplementary Fig. 4). For
brain-wide parametric analyses, positive ChaCo values were
therefore modeled linearly on the logarithmic scale with a
Gaussian response function.
Figure 2a visualizes the change in structural disconnection in
individual cortical regions from before randomization to 22–36 h
after stroke. In the placebo group, loss of connectivity was most
likely in the temporal lobe, the insular, pre- and postcentral
cortices, inferior and superior parietal cortices as well as in
subcortical areas (thalamus, caudate nucleus, putamen). In the
alteplase group, substantial loss of connectivity appeared more
restricted, occurring mostly in the temporal lobe, pre- and
postcentral and inferior temporal gyri. Differences in structural
disconnection between treatment arms are represented in Fig. 2b.
Before randomization, there were no significant differences in
structural disconnection in any region (Mann–Whitney U
P > 0.05). After 22–36 h, we observed an excess of disconnection
in the placebo group compared to the alteplase group in the
cingulum, para-, postcentral and supramarginal cortices, in the
adjacent areas of the superiorfrontal and transverse temporal gyri
as well as the precuneus and the caudate nucleus (uncorrected
two-sided Wilcoxon P < 0.05). Interaction effects between time
and treatment on structural disconnection are displayed in
Fig. 2c. Numerically, within-subject change in disconnection in
the placebo group was most likely to exceed that in the alteplase
group in the transverse und superior temporal, postcentral,
inferior frontal, and supramarginal gyri, the anterior cingulum as
well as caudate nucleus. Detailed numerical results are reported in
Supplementary Table 3.
After these descriptive analyses, we considered the profile of
ChaCo scores across all pre-specified brain regions to assess
structural disconnection at a global scale. Parametric modeling
revealed a statistically significant interaction between time and
treatment on global structural disconnection with more pro-
nounced changes in the placebo group (Placebo: ChaCoT2/
ChaCoT1= 1.67, CI95% [1.49, 1.88]; Alteplase: ChaCoT2/Cha-
CoT1= 1.16, CI95% [1.02, 1.32]; P= 7.40 × 10−4; Table 1, Fig. 3).
There was no evidence of spatial heterogeneity of this interaction
effect. Effects of time and treatment allocation on connectivity,
both for individual brain areas and pooled parametrically, were
confirmed in an analogous analysis using the AAL atlas
(Supplementary Tables 4, 5 and Supplementary Figs. 5–7).
Progressive network disruption in combination with infarct
growth, but not infarct growth alone, mediated the beneficial
effect of thrombolysis. As shown above, treatment with alteplase
was associated with better clinical outcome and less infarct
growth. Also, infarct growth was strongly associated with unfa-
vorable clinical outcome. In a causal mediation analysis adjusted
for age, baseline NIHSS score, and pre-randomization DWI lesion
volume, however, the effect of alteplase on the proportion of
Fig. 1 Pattern and magnitude of structural disconnection induced by acute ischemic stroke lesions prior to randomization illustrated on a three-dimensional
template in standard MNI space. Lesions were segmented on diffusion-weighted images (DWI) and mapped onto reference tractograms from 73 healthy
subjects using the NeMo Toolbox. Spheres are located at the center of gravity of each of 86 brain regions of the Desikan–Killiany parcellation. Volume
indicates magnitude of average change of connectivity with larger sizes indicating higher degree of disconnection. Colors indicate assignment of brain
regions to frontal (cerulean), parietal (sun), temporal (dark cyan), occipital (summer sky) and limbic (violet red) lobes, or subcortical structures (orange).
In the coronal section, the brain template is shown using the neurological convention. This Figure was created using the NeMo toolbox39.
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patients achieving a modified Rankin scale score of 0 or 1 after
3 months (favorable outcome) was not significantly mediated by
lesion growth (natural indirect effect 1.04, CI95% [0.96, 1.17],
proportion mediated 8.3%, CI95% [−8.0, 32.6]%, P= 0.193).
We next investigated whether the clinical effect of thrombo-
lysis was better explained by considering change in structural
connectivity as an additional mediator. As expected, this change
in connectivity was not independent of lesion growth, with
higher infarct growth rates associated with more pronounced
loss of connectivity in all brain regions except the frontal and
temporal poles (Supplementary Fig. 8). The associations
between lesion growth and connectivity loss were strongest in
the pre- and postcentral and supramarginal cortices, the insula,
and the caudate, reflecting our selection of anterior-circulation
stroke patients.
In order to focus our analysis on brain regions with relevant
connectivity alterations regarding treatment and clinical outcome,
Fig. 2 Non-parametric mass univariate analysis of effects of time and treatment allocation on loss of connectivity. In each panel, measures of effect
size (top) and surprisal51,62, i.e. s=−log(P), (bottom) for each cortical parcel of the Desikan–Killiany atlas, are visualized as colored regions on the
FreeSurfer standard template brain. The logarithmic scale for surprisal is identical across panels. Dark grey patches on surface representations correspond
to uncorrected P values > 0.05. For corresponding numerical data see Supplementary Table 3. a Effect of time is quantified as the estimated probability
ℙ(T2 > T1) that network disruption scores are higher at T2 than at T1 and assessed using Wilcoxon signed-rank tests. b Effect of treatment allocation is
quantified as the estimated probability ℙ(P > A) that network disruption scores are higher in the placebo than in the alteplase group and assessed using
Mann–Whitney U tests. c Interaction between time and treatment allocation is quantified as the estimated probability ℙ(ΔP >ΔA) that within-subject
change (T2–T1) of network disruption scores is higher in the placebo than in the alteplase group and assessed using Mann–Whitney U tests. All P values
are two sided.
Table. 1 Effect of time (T1 before and T2 after
randomization) and treatment (placebo or alteplase) on
global score of structural disconnection factoring in the
effect of potential spatial heterogeneity in investigated
brain areas. Shown is an ANOVA table for the linear-mixed
effects model log(ChaCo+) ~ time × treatment+ ROI ×
(time+ log(volume))+ (1|subject), where the last term
represents a random intercept for each subject. Two-sided
P values are calculated from type II Wald χ2 tests, as
implemented in the R package car25.
χ² d.o.f. P value
Main effects
Time 38.0 1 7.12e−10
Treatment 0.055 1 0.815
Time: Treatment 11.4 1 7.40e−4
Covariates
log(Volume) 2133 1 <1e−300
Spatial heterogeneity
ROI 27717 41 <1e−300
ROI: Time 71.6 41 0.002
ROI: log(Volume) 1468 41 <1e−300
d.o.f. degrees of freedom, ROI region of interest Fig. 3 Progression of average structural disconnection after stroke
from before (T1) through 22–36 h after (T2) randomization (n= 269
biologically independent subjects examined at two time points), stratified
by allocation to placebo (persian green) or alteplase (tory blue). Circles
represent structural disconnection quantified by mean average logarithmic
Change of Connectivity (ChaCo) scores for the two groups. Vertical bars
indicate 95% confidence intervals. The increase in structural disconnection,
i.e. progressive loss of connectivity, is statistically significantly higher in the
placebo group (P= 7.40 × 10−4 after adjustment for lesion volume and
spatial heterogeneity, see also Table 1 for corresponding values).
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-22786-w
4 NATURE COMMUNICATIONS |         (2021) 12:2590 | https://doi.org/10.1038/s41467-021-22786-w |www.nature.com/naturecommunications
we first ranked brain regions in terms of their alteplase-
responsiveness, i.e. association of connectivity change with treat-
ment allocation (Table 2, left column), and clinical eloquence, i.e.
association of connectivity change with favorable clinical outcome
(mRS 0–1, Table 2, right column) using univariate linear and
logistic regression analyses adjusted for age, baseline NIHSS score,
and baseline lesion volume. We note that alteplase-responsiveness
corresponds to the effect shown in Fig. 2c, where, however, no
adjustment for covariates was performed. Overall, there was a high
degree of similarity between both rankings (Spearman rank
correlation 0.42, P 0.006). Connectivity changes in four brain
regions showed significant associations with both treatment
allocation and functional outcome as highlighted in Table 2
(supramarginal, postcentral, lateral orbitofrontal as well as the
posterior cingulate cortex). These were explored as potential
mediators of the effect of thrombolysis on functional outcome.
Varying the thresholds for including a region according to either
alteplase responsivity or clinical eloquence independently from very
conservative (considering only the region with the strongest
association) to very liberal (considering up to nine or fifteen
regions, respectively) led to the identification of seven distinct
models (Fig. 4a). These models contained the connectivity changes
of up to four brain regions as mediators, their specific compositions
are shown in Fig. 4b. The natural indirect effect of thrombolysis on
functional outcome mediated jointly through infarct growth and
connectivity loss in those sets of regions varied from 1.08 (CI95%
[0.97, 1.24]%) to 1.19 (CI95% [1.03, 1.41]%), corresponding to
proportions mediated between 15.4% (CI95% [−3.9, 45.7]%) and
33.4% (CI95% [8.8, 77.4]%) (Fig. 4c). As expected, mediation effects
in these seven models were not independent, with bootstrap
estimates of the correlation between natural indirect effects ranging
from 0.53 to 0.98 (Fig. 4d). Step-down rejection thresholds for the
null hypotheses of no mediation effect derived from the joint
distribution of resampled indirect effects are shown in Fig. 4e. All
seven observed indirect effects exceeded their respective threshold,
thus providing evidence in favor of significant mediation in all
models considered, while controlling the false discovery rate at 5%.
A direct comparison of the models including only lesion growth
(Fig. 5a) and the combination of lesion growth and connectivity
changes (Fig. 5b) showed that the natural indirect effect mediated
jointly through infarct growth and connectivity loss exceeded the
NIE mediated through infarct growth alone by a factor of between
1.04 (CI95% [0.98, 1.12]%) and 1.14 (CI95% [1.02, 1.29]%) (Fig. 4f).
For five of the seven models under consideration, this excess effect
of connectivity change was statistically significant, as indicated by
the bootstrap 95% confidence interval of the ratio of NIEs not
containing 1. Connectivity change in brain regions that were not
preselected by association with both treatment and outcome did not
have, on average, an excess mediating effect as shown by the
distribution of corresponding joint indirect effects centering around
the indirect effect of infarct growth alone (Fig. 4g).
In an analogous analysis based on the Automatic Anatomical
Labelling (AAL) atlas, results were qualitatively similar, albeit
with somewhat smaller effect sizes that failed to reach statistical
significance (Supplementary Fig. 9). Specifically, the selection of
brain regions based on the association between their connectivity
change and both treatment allocation and functional outcome
identified three mediation models comprising of combinations of
inferior parietal and middle cingulate cortices. In conjunction
with infarct growth, connectivity change in these regions
mediated between 12.4% (CI [−5.5, 39.4]%) and 16.1% (CI95%
[−5.5, 44.5]%) of the total clinical effect of thrombolysis. An
additional model, corresponding to the best performing Model 1
in Fig. 4, was specified manually and included, as mediators, the
inferior orbitofrontal, supramarginal, and angular cortices, as well
as the cingulum. Together with infarct growth, local connectivity
loss in these regions mediated 27.6% (CI95% [−2.3, 64.9]%) of the
total effect of thrombolysis on functional outcome. The combined
natural indirect effect exceeded the NIE of infarct growth alone
by a factor of 1.11 (CI95% [0.96, 1.25]).
Discussion
In this secondary analysis of structural connectome disruption in
patients with anterior-circulation stroke from the WAKE-UP
trial, we obtained two major results. Firstly, treatment with alte-
plase impeded growth of the ischemic lesion as well as stroke-
induced loss of connectivity measured 22 to 36 h after stroke.
Progression of structural disconnection was attenuated in clini-
cally eloquent brain areas involved in motor control and speech.
Secondly, averted loss of connectivity, in conjunction with pre-
vented infarct growth, explained up to 33% of the total effect of
alteplase on favorable clinical outcome measured by the modified
Rankin scale 90 days after stroke. We observed a mediating effect
of prevented connectivity loss on favorable outcome beyond the
effect of lesion growth alone.
Consistent with the primary analysis of the WAKE-UP trial,
stroke volumes in this subgroup of patients were small and did
not differ between groups (placebo and alteplase) prior to ran-
domization. In contrast to the main results of WAKE-UP, where
neither final lesion stroke volumes nor lesion growth were sig-
nificantly different between patients receiving alteplase or
placebo13, we observed reduced lesion growth in the thrombolysis
group. This disparity can be attributed to exclusion of patients
with posterior-circulation and infratentorial stroke, where the
growth of ischemic lesions is usually less extensive. Compared to
previous large clinical trials, lesion volumes in WAKE-UP were
determined from MRI (DWI) images, allowing a more accurate
segmentation of infarcts compared to non-contrast CT and thus
contributing to a higher sensitivity for detecting group differences
in the evolution of lesion volume. The selection of patients with
anterior-circulation stroke resulted in a lesion pattern focussed on
structures in the deep territory of the middle cerebral artery,
predominantly involving white matter structures and the sub-
cortical grey matter (Supplementary Fig. 2).
A reduction of lesion size after randomization was observed in
24.5% of patients (66/269), matching previously reported rates of
reversible DWI lesions in acute ischemic stroke22, which may
indicate salvage of brain tissue. The association between DWI
reversal and true reversal of cerebral ischemia is, however, con-
founded by several pathophysiological and imaging factors, and
can vary with time to treatment, severity of perfusion deficits,
lesion size, and site of vascular occlusion22.
In accordance with this lesion distribution, structural dis-
connections induced by stroke lesions were most pronounced in the
basal ganglia as well as cortical areas of the frontal, parietal and
temporal lobes adjacent to the central sulcus. We observed pro-
minent disconnections of cortical areas such as the pre- and post-
central gyrus which are linked to subcortical lesion sites by long
white matter fiber bundles such as the corticospinal or thalamo-
cortical tract23. The observed anatomical pattern of connectome
disruption corresponds well with previous observations in a group
of 41 patients with acute ischemic stroke analyzed by a similar
methodological approach using the Network Modification (NeMo)
tool24. In this previous work, disconnection of brain areas involved
in motor control and language was also associated with increases in
the NIHSS score, indicating a relation between the pattern of
structural disconnection and severity of clinical dysfunction24.
In our group of patients, a loss of global structural connectivity
was observed over the first 22 to 36 h after stroke, manifesting as
increasing Change of Connectivity (ChaCo) scores across nearly all
brain areas. Growth of DWI lesions would be expected to lead to
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Table 2 Selection of brain regions for multiple mediation analysis.
The associations of change in connectivity from before to 22–36 h after randomization with treatment allocation (left) and favorable outcome (mRS 0–1 after 3 months, right) were assessed using linear
and logistic regressions, respectively. Age, baseline NIHSS score and baseline lesion volume were included as covariates. Effect sizes were quantified by standardized regression coefficients (Beta) and
standardized odds ratios (OR). Regions were ranked independently by the statistical evidence for a non-vanishing association between connectivity change and treatment/outcome and considered a
potential mediator of the effect of thrombolysis if neither of the two 95% confidence intervals was compatible with the absence of an association (horizontal black lines). Matching regions are connected
by lines to indicate similarity of the two rankings. Colors indicate assignment to frontal (cerulean), parietal (sun), temporal (dark cyan), occipital (summer sky) and limbic (violet red) lobes, or subcortical
structures (orange).
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Fig. 4 Results of multiple mediation analysis, adjusted for age, baseline NIHSS score and pre-randomization lesion volume. a Selection of brain regions
by decreasing strength of association between treatment allocation and connectivity change (horizontal axis) and connectivity change and functional
outcome (vertical axis). Each colored patch corresponds to a mediation model including, as mediators, infarct growth as well as connectivity change in the
intersection of the i most alteplase-responsive (horizontal axis) and j most clinically eloquent (vertical axis) regions. Identical color coding is applied for the
following subgraphs (b, c, e–g) to identify underlying referred models. b Composition of resulting seven mediation models comprising connectivity change
in up to four brain regions. c Proportion of total effect of thrombolysis on favorable clinical outcome (mRS 0–1) mediated jointly through infarct growth and
connectivity change in different sets of brain regions (n= 263 independent subjects). Solid dots represent point estimates. Vertical bars indicate 95% bias-
corrected confidence intervals obtained from bootstrap with k= 10,000 replicates, stars (*) highlight models in which the 95%-CI does not contain 0%. d
Empirical correlation between natural indirect effect estimates corresponding to different mediation models. Darker shades of green correspond to stronger
correlations as indicated numerically in the left upper triangle of the matrix. e Step-down procedure to control the false discovery rate in the joint
assessment of multiple mediation models at 5%. Models are ordered by their empirical natural indirect effect, indicated by triangles; beginning with the
strongest effect, null hypotheses of no mediation effect are sequentially rejected as long as NIEs exceed their respective rejection threshold indicated by
the black step line (median of k= 100 bootstrap replicates). Shading indicates 95% confidence intervals for the rejection line. f Point estimates (solid dots)
and 95% confidence intervals (vertical bars) for the ratio between joint natural indirect effects of infarct growth and connectivity loss and the NIE of infarct
growth alone (bootstrap with k= 10,000 replicates; n= 263 independent subjects). g Null distribution of empirical natural indirect effects mediated jointly
through infarct growth and connectivity change in random subsets of all brain regions. Horizontal lines indicate the mediation effects of infarct growth
alone (black, NIE 1.04) and infarct growth in combination with connectivity change in alteplase-responsive clinically eloquent areas (colored). NIE Natural
indirect effect, SM supramarginal, PCing posterior cingulate, PoC postcentral, Cau caudate, ICing isthmus cingulate, PreC precentral, SupF superiorfrontal,
CACing caudal anterior cingulate, PH parahippocampal, CMF caudal middle frontal, Ins insula, Tha thalamus, LOF lateral orbitofrontal, POrb pars orbitalis,
Fus fusiform, TT transverse temporal, SupP superior parietal, MOF middle orbitofrontal, RACing rostral anterior cingulate.
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larger disruptions of the structural connectome. Similarly, lesion
reduction can be associated with an increase in connectivity of
specific brain areas. Biologically, thusly measured increased con-
nectivity does not necessarily indicate de-novo growth of neurons at
or through the site of ischemic injury but could rather represent the
recovery of signal conduction along axonal projections running
through salvageable brain tissue. Cytotoxic edema surrounding the
ischemic core is likely to contribute to fluctuations of clinical deficits
in stroke patients;25,26 we speculate that similarly, on a cellular level,
reversal of cytotoxic enema as a consequence of reperfusion could
lead to improved signal transduction along non-irreversibly
damaged neurons via reduced physical pressure and the restora-
tion of cellular metabolism27,28. However, given the unresolved
question of an optimal ADC threshold to define the irreversibly
damaged ischemic core, this pathophysiological interpretation of
increased connectivity in the context of lesion size reduction has to
remain speculative.
Our findings demonstrate that progression of structural dis-
connection was less extensive in patients treated with alteplase than
in those receiving placebo. Notably, this effect of thrombolysis on
preserved connectivity remained significant in a model adjusted for
lesion volumes. This indicates that measures of structural dis-
connection contain information on the impact of stroke lesions and
treatment effect of alteplase on brain structure that carry additional
value compared to information gained by measuring lesion volumes
alone. It emphasizes the significance of the anatomical pattern of
infarction and is consistent with studies of lesion-symptom infer-
ence in stroke14,29. On a local scale, treatment-dependent attenua-
tion of structural disconnections was numerically strongest in
functionally eloquent areas adjacent to, but not directly affected by,
the lesion, such as the inferior frontal, postcentral, supramarginal,
and superior temporal gyrus (Fig. 2). However, these findings have
to be interpreted with caution since there was no statistically sig-
nificant heterogeneity.
Systemic thrombolysis is strongly linked to reperfusion, pre-
servation of brain tissue, and favorable clinical outcome. However,
currently used imaging biomarkers, such as infarct volume, are
often poor surrogates for clinical outcome because they ignore the
location-specific impact of a lesion on brain networks. Treatment
with alteplase has been shown to impede the growth of the ischemic
lesion, and to be associated with smaller final infarct volumes due to
the restoration of blood flow in previously occluded arteries30.
However, attenuation of lesion growth can be absent despite clinical
treatment effects, even in patients with larger lesion volumes, after
successful recanalization of large vessel occlusion12. In our sub-
group analysis of the WAKE-UP trial, stroke lesion growth was
reduced after alteplase treatment and associated with poor clinical
outcome. Yet, in a causal mediation analysis, lesion growth did not
explain a significant proportion of the clinical effect of alteplase on
good outcome. While not statistically significant, the point estimate
of the proportion mediated, 8.3%, is consistent with a recent study
analyzing the mediation effect of final infarct volume on functional
outcome in a larger cohort of acute stroke patients treated with
endovascular therapy31. We could demonstrate that by considering
averted loss of connectivity as additional structural mediators, up to
a third of the total effect of thrombolysis on clinical outcome could
be explained. The observed effect is in line with previous findings
demonstrating higher clinical specificity of structural disconnection
compared to purely focal measures of ischemic damage in stroke20.
This finding in our patients is clinically plausible given the spatial
pattern of brain regions in which loss of connectivity was responsive
to alteplase treatment, (Fig. 4) and the use of the modified Ranking
scale as a clinical outcome score in WAKE-UP. Specifically, our
mediation models identified pronounced attenuation of dis-
connection in cortical areas involved in sensorimotor and language
functions such as the postcentral cortex and inferior parietal lobule
which would translate into better recovery measured by the mRS. In
addition, averted connectivity loss in the posterior cingulum, a
strategic and highly connected brain region involved in attention
and various emotional and cognitive functions, featured promi-
nently in all relevant mediation models demonstrating the surplus
effect beyond lesion growth alone. Connectivity changes in brain
areas at the center of the stroke lesion distribution in this cohort,
such as the basal ganglia, insular or precentral gyrus did not show a
large treatment response (Table 2), and were therefore not con-
sidered as mediators of the clinical effect of thrombolysis on
favorable clinical outcome. While these findings are plausible in
suggesting that the connectivity-preserving effect of thrombolysis
might be most clinically relevant in connections supported in the
ischemic penumbra around the infarct core, such an interpretation
should be investigated further in future studies including more
heterogeneous populations and alternative clinical outcome mea-
sures to determine which brain regions, viewed from a network
perspective, are most sensitive to treatment effects and most critical
for recovery.
In our study, we have chosen the mRS as a measure of func-
tional outcome after stroke analogous to the primary endpoint of
the WAKE-UP trial. Although the mRS is almost universally
ΔChaCo region n *
⋮
ΔChaCo region 2 *














(mRS 0-1 at 3 months after stroke)
ba
Fig. 5 Diagrammatic representation of the causal models used in mediation analyses of the effect of thrombolysis with alteplase on functional
outcome through structural parameters of infarct progression. Favorable clinical outcome was defined as mRS 0–1, 3 months after stroke. aMediation by
single mediator infarct growth. b Mediation by progressive loss of local structural connectivity (ΔChaCo) in multiple brain regions. As a post-treatment
confounder of the relation between change in connectivity and functional outcome, infarct growth was included as an additional mediator. Adjustment for
covariates (age, lesion volume and NIHSS score at baseline prior to randomization) was carried out as marked by the asterisk and indicated explicitly in
model a. mRS modified Ranking Scale; NIHSS National Institute of Health Stroke Scale.
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applied as an outcome measure in large clinical stroke trials, its
validity in measuring functional outcome of stroke patients has
been debated32. Specifically, the mRS broadly assesses the degree
of disability or dependence in the daily activities, which strongly
depend on intact motor functions. We speculate that our
approach of detecting treatment-responsive areas of the structural
connectome might also yield interesting insights into brain
functions that rely on more extensive and complex brain net-
works, such as language, cognitive or affective functions relevant
in stroke recovery21. Therefore, future studies using alternative
outcome measures are needed.
Our results demonstrate the relevance of preserving structural
connections in acute stroke treatment and offers a promising
alternative to predict clinical recovery beyond conventional MRI
imaging markers such as ischemic lesion volume. The strengths of
our study are the use of well-defined stroke lesion segmentations
based on the identification of ischemic tissue from MRI DWI
within the framework of a large multicentre prospective clinical
stroke trial. We furthermore apply an innovative and intuitive
approach to estimate disturbances in structural brain networks that
has previously been shown to be relevant for predicting clinical
behavior and recovery in stroke populations21,24. Lastly, our sta-
tistical approach included adjustments for multiple parameters
affecting clinical recovery, such as initial lesion volume and lesion
growth. Although the current methodological approach still
involves some manual data postprocessing and user interaction, we
envision a more automated, time-efficient workflow for estimating
structural disconnection from clinical stroke imaging data. Given
the availability of automated lesion segmentation software in acute
stroke diagnostic, an interesting approach would be to amend these
tools with pre-installed structural connectomes that estimate the
global or local disruptions in structural connectivity and its clinical
impact depending on the choice of treatment and expected pattern
of lesion growth based on the cerebral vascular architecture. Fur-
thermore, we believe that future models and software applications
based on automated classification algorithms to predict stroke
outcome should take into account structural network changes as a
relevant imaging marker in acute stroke.
In this study, structural connectivity damage was estimated
indirectly by embedding stroke lesions masks in connectomes of
healthy subjects. We have previously measured structural con-
nectivity changes directly based on DTI and fiber tracking in a
smaller group of acute stroke patients and reported a pattern of
structural disconnection closely resembling our current
findings19. However, substantial confounders exist when directly
measuring acute stroke patients using the necessary high-
resolution structural MRI protocols, such as excessive head
movement artifacts specifically occurring in patients with more
severe clinical deficits. There is also a potential selection bias
towards more mildly affected patients who are better able to
tolerate comparatively long examination times mandatory for
robust measurement of signals in diffusion imaging. Collecting
large datasets of stroke patients covering a broad range of lesion
distributions and clinical deficits to achieve generalizable results is
an additional challenge. Given these limitations, indirect esti-
mation of disturbed structural connectivity in stroke is a valuable
alternative for understanding the impact of focal lesion on long-
range anatomical disconnections in relation to clinical behavior.
In line with this hypothesis, several previous studies have suc-
cessfully related indirect measures of disconnection to clinical
phenotypes in stroke and small vessel disease21,33–35. Griffis et al.
recently reported a mediation effect of indirect approximations of
structural disconnection on empirically measured changes of
resting-state functional connectivity in stroke patients, thus pro-
viding support for the functional relevance of indirectly assessed
disconnectivity patterns20. The NeMo Tool used in our analysis
has been shown to generate valid markers of disconnection
that can help identify brain areas at risk of tissue loss after
stroke and predict 6-months post-stroke outcome in various
domains21,36. Associations between indirect connectivity mea-
sures (“disconnectomes”) and neuropsychological performances
were also reported in patients with focal brain lesions of various
etiologies34. Of note, analysis of reference data from different age
groups (20 to 60 years) did not reveal a significant impact of age
on resulting measures of structural disconnectivity. Notwith-
standing, the marker of disconnectivity change employed in this
study (ChaCo scores) has to be considered as a proxy of patho-
logical neuronal disconnection contingent on the validity of the
underlying reference connectome reconstruction methodology.
Specifically, DTI tractography, by inferring connectivity from
local diffusion orientation fields, is less reliable in brain areas with
complex axonal fiber bundle configuration such as crossing and
fanning fibers37. This effectively results in the generation of false-
positive (erroneous) fiber tracts, whereas missing detections of
valid fiber bundles (false-positive results) are less commonly
observed38. Some disambiguation of complex fiber tract config-
urations can be achieved by technical improvements in diffusion
tensor estimation such as High Angular Resolution Diffusion
Imaging (HARDI), which was applied in our current analysis39,40.
In terms of indirect estimations of structural connectivity changes
as applied in our study, the aforementioned limitations would
mainly translate to false-positive signals for brain areas with
invalid association to the underlying stroke lesions. Although we
have not noted a substantial amount of implausible disconnection
in brain regions with anatomically unlikely connectivity to the
observed lesion pattern (such as posterior brain areas, Fig. 1,
Supplemental Figs. 4–6), we cannot exclude a methodological bias
from DTI tractography affecting our results.
Moreover, by exploiting knowledge about the average anatomy
of white matter tracts encoded in normative tractograms to
extrapolate subject-specific lesion masks to expected changes in
neural connections between grey matter areas, indirect lesion
network mapping reflects the effects of individual focal lesions on
a normative structural brain network39. It is therefore agnostic to
inter-individual variability in white matter anatomy and integrity.
The validity of our approach is thus contingent on the plausible
assumption that, on average, inter-individual differences are, on
average, much smaller than lesion-induced network disruptions.
Given these limitations, there is a further need for direct com-
parison of direct and indirect measures of altered structural
connectivity in relation to clinical phenotypes.
There are several additional limitations to our study that have
to be considered. Firstly, the subset of the WAKE-UP trial cohort
analyzed in this study comprised patients with anterior-
circulation stroke, for whom follow-up DWI and FLAIR ima-
ging after 22–36 h of sufficient quality for lesion segmentation
was available. Clinical characteristics of excluded patients were
similar to the study population, and therefore the risk of sig-
nificant selection bias seems low. While it would be interesting to
investigate the pattern of disconnection and its response to
thrombolytic treatment in posterior-circulation strokes, the small
number of such lesions in the WAKE-UP trial and the expected
heterogeneity of connectivity profiles across lesion sites (specifi-
cally infratentorial strokes) led us to exclude these patients from
analysis. Secondly, while the connectivity-preserving effect of
thrombolysis could be demonstrated robustly in both the
Desikan–Killiany and the AAL parcellation-based analysis,
mediation effects of preserved connectivity could be reproduced
only numerically in the AAL-based analysis but failed to reach
statistical significance there. We believe this to be due to the
higher spatial specificity of the Desikan atlas, which is derived
from FreeSurfer’s surface-based cortical parcellation stream,
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whereas the AAL atlas is primarily volumetric, and tends to be
more limited in its resolution of the intragyral grey-white matter
interface. Thirdly, we are confident that our mediation model
Fig. 5b is correctly specified; in the absence of a robust sensitivity
analysis framework for models with multiple mediators, however,
we cannot exclude the presence of unmeasured confounders of
the relationship between connectivity loss and functional
outcome41,42. Lastly, concerning the population of our study,
patients were randomized in the WAKE-UP trial using an ima-
ging paradigm that identifies patients whose stroke had likely
occurred within the preceding 4.5 h, and who thus presented in a
therapeutic time window for thrombolysis43. Future studies
are needed to investigate the effect of earlier or later onset-
to-treatment time intervals regarding trajectories of structural
disconnection and outcome.
In conclusion, this post-hoc analysis of the WAKE-UP trial data
provides evidence that systemic thrombolysis prevents progressive
loss of structural connectivity after ischemic stroke, and that the
associated preservation of the structural connectome contributes to
mediating the clinical effect of thrombolytic treatment on functional
outcome. Thus, while thrombolysis-induced reperfusion prevents
tissue damage as measured by both lesion volume and loss of
connectivity, the latter appears to be of independent relevance for
clinical outcome. When evaluating the benefit of reperfusion ther-
apy, structural connectivity may therefore provide an additional and
perhaps more specific neuroimaging marker of treatment response
beyond stroke lesion volume.
Methods
Study design. In this post-hoc analysis, we reviewed imaging and clinical data of all
patients randomized in the WAKE-UP trial13. The WAKE-UP trial was an inter-
national, double-blind, placebo-controlled randomized clinical trial that studied the
efficacy and safety of systemic thrombolysis with alteplase in acute ischemic stroke
patients with unknown time of symptom onset. Patients were included after MR
imaging had demonstrated an acute ischemic lesion in diffusion-weighted sequences
without established FLAIR hyperintensity. This mismatch had previously been shown
to indicate that the stroke most likely occurred within 4.5 h from imaging43. The
WAKE-UP trial demonstrated that thrombolysis in patients with unknown symptom
onset is effective and safe if this imaging criterion is fulfilled.
For our secondary analysis, we included patients with isolated anterior-
circulation stroke who received diffusion-weighted imaging (DWI) and fluid-
attenuated inversion recovery (FLAIR) imaging at two pre-specified time points of
the WAKE-UP trial. We included data from initial MRI examinations prior to
randomization (T1) and follow-up imaging 22 to 36 h after randomization (T2).
Due to the small number of patients with posterior-circulation infarcts and the
substantial heterogeneity of structural network disturbance between patients with
anterior- and posterior-circulation lesions, we restricted our analysis to patients
with stroke in the anterior circulation. We excluded data from patients with
bilateral stroke, as well as imaging data of insufficient quality, i.e. those exhibiting
large motion artifacts, preventing correct segmentation and registration of stroke
lesions. Written informed consent by either patients or their legal representatives
was provided according to relevant regulations. The WAKE-UP trial was approved
by Ethics Committee of the Hamburg Chamber of Physicians, the German Federal
Institute for Drugs and Medical Devices, as well as by local competent authorities
and ethics committees at each study site.
Imaging data processing and analysis. Imaging data were analyzed using a
dedicated software developed for the WAKE-UP trial (Stroke Quantification Tool,
SONIA, v1.0) based on previous methods and functionalities of a stroke imaging
toolbox developed in-house44,45. In summary, individual DWI and FLAIR datasets
were coregistered using rigid transformation. Maps of apparent diffusion coefficient
(ADC) were calculated based on two DWI datasets chosen automatically with b-
values of 0 s/mm² and between 500 s/mm² and 1500 s/mm² according to the imaging
protocol of the individual study site. Stroke lesions were segmented on ADC maps
using a semi-automated procedure with initial manual delineation and secondary
automated refinement based on an ADC threshold of 620mm²/s. All images were
visually checked for quality and plausibility of segmentation results by cross-modal
inspection of FLAIR and ADC maps. All segmentations were reviewed by two neu-
rologists experienced in acute stroke treatment and stroke imaging research (BC and
AK) and were reviewed a second time by a board-certified neurologist (BC) and
manually corrected, if necessary. Lesion volumes were calculated based on final lesion
segmentations in native space. Binary lesion masks were transformed to MNI space
by applying linear and non-linear registrations. All lesions were visually checked after
transformation to MNI space and corrected if necessary.
Quantification of structural network disruption. Binary lesion masks were
entered into the Network Modification (NeMo) toolbox39 for Matlab46 to estimate
structural disconnection at the level of individual grey-matter regions, defined in
the Desikan–Killiany FSL47 and Automated Anatomical Labelling (AAL)48 atlas
with 86 and 116 regions, respectively. In summary, the NeMo tool quantifies
disconnections in the brain’s structural network by mapping stroke lesions from
clinical imaging data onto a collection of connectomes from 73 healthy partici-
pants. The NeMo tool has been applied to investigate lesion-dysfunction
relationships24, white- and grey-matter pathologies in normal aging49, as well as
prediction of 6-month clinical outcome after stroke21. Specifically, for each brain
area and each of 73 whole-brain reference tractograms provided in the NeMo
toolbox, the number of streamlines connected to this region and running through
the site of the lesion was counted and divided by the total connectivity of the
region. The average of these 73 proportions, referred to as the Change of Con-
nectivity (ChaCo) score, was computed as a measure of local structural dis-
connection. In this score, values of zero indicate that the streamlines originating
from a grey-matter area do not pass through the stroke region at all (no dis-
connection), while the maximal value one represents complete disconnection of a
piece of cortex from the rest of the network. In our analysis, ChaCo scores were
computed for stroke hemispheres only, which, after exclusion of the cerebellar
regions, were parcellated into 42 (Desikan–Killiany) or 45 (AAL) areas. Although
our sample did not include patients with cerebellar stroke and the cerebellum was
not investigated as a region of interest, we note that cerebellar streamlines con-
tributing to the connectivity of other affected regions, such as the thalamus, were
not discarded. We calculated ChaCo scores from imaging data both prior to and 22
to 36 h after randomization. Given that at both times, network disruption was
computed from the same of reference tractograms, the difference in ChaCo scores
was interpreted as the absolute within-subject loss of connectivity.
Clinical data. We collected clinical data from the database of the WAKE-UP trial,
including patient age at symptom onset, National Institutes of Health Stroke Scale
(NIHSS) score at presentation and functional outcome 90 days after stroke. In
addition, information on randomization (treatment with alteplase or placebo) was
collected. For our analysis, we defined the clinical endpoint following the primary
efficacy endpoint of the WAKE-UP trial as a score of 0 or 1 point on the modified
Rankin Scale (mRS) of neurologic disability (ranging from 0 [no symptoms] to 6
[death]), assessed 90 days after stroke.
Statistical analysis. Baseline characteristics, including age and NIHSS score at initial
presentation, were compared between patients assigned to treatment with placebo and
alteplase using a two-sample t-test and Mann–Whitney U test, respectively.
Growth of lesion volume between T1 (initial MRI prior to randomization) and
T2 (MRI at 22 to 36 h after randomization) was assessed using Wilcoxon signed-
rank tests50. A Mann–Whitney U test was performed to compare absolute within-
subject lesion volume change between placebo and alteplase groups and assess the
effect of treatment on infarct growth. In addition, generalized linear-mixed effects
modeling was carried out to assess the interaction effect between treatment and
time on lesion volume in a parametric setting. An unconditional logistic regression
model, adjusted for age, baseline NIHSS score and baseline lesion volume, was
fitted to associate the log odds of achieving an mRS score of 0-1 with infarct
growth. The adjusted odds ratio was tested against the null hypothesis of no
association using a Wald t-test and presented with a 95% confidence interval
obtained from profiling the likelihood function.
For each brain area, the evolution of ChaCo scores over time, differences between
placebo and alteplase groups, as well as the interaction between treatment and time,
were explored non-parametrically by contrasting median connectivity scores within
and between groups. For illustration we also report the Shannon information or
surprisal as a measure of the information against the hypothesis of no effect encoded
in the data51. While these are derived from Wilcoxon signed-rank and
Mann–Whitney U tests, no formal null-hypothesis significance testing was intended
and, consequently, no adjustment for multiple testing was performed. To assess our
main hypothesis with regards to the global effects of time and treatment on ChaCo
scores, linear-mixed effects regressions were fit to pooled data from all areas. In a two-
component mixture model, the probability of non-zero ChaCo score was first
analyzed using logistic regressions; positive ChaCo values were then transformed
logarithmically and analyzed with a constant-variance Gaussian response distribution.
Given the potential confounding effect of infarct size, all parametric models included
logarithmically transformed lesion volume as a covariate.
Statistical analyses were performed in the R Statistical Computing Environment
(version 4.0.2)52.
Mediation analysis. To explain the mechanisms underlying the clinical benefit of
systemic thrombolysis with alteplase, we performed a causal mediation analysis in
the counterfactual framework53. We specified the hypothetical causal models
represented in Fig. 5, in which the clinical effect of thrombolysis on functional
outcome would be mediated either through lesion growth alone (a) or through the
combination of lesion growth and structural connectivity decline in multiple brain
areas (b). Infarct growth was included as a mediator in model (b) to account for its
confounding effect on the relation between connectivity decline and functional
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-22786-w
10 NATURE COMMUNICATIONS |         (2021) 12:2590 | https://doi.org/10.1038/s41467-021-22786-w |www.nature.com/naturecommunications
outcome. Both models included the pre-treatment covariates age, baseline NIHSS
and pre-randomization lesion volume. Given the inclusion of both baseline lesion
volume and infarct growth in all models, final infarct volume was not explicitly
included to avoid collinearity.
The strength of mediation was quantified using natural effects in the
counterfactual framework54. Specifically, natural direct, natural indirect and total
effects were calculated on the odds ratio scale as
NDE ¼ PT;MjP=ð1 PT;MjPÞ
PP;MjP=ð1 PP;MjPÞ
; NIE ¼ PT;MjT=ð1 PT;MjTÞ
PT;MjP=ð1 PT;MjPÞ
; TE ¼ NIE ´NDE;
ð1Þ
where PT, M|T and PP, M|P are the expected probabilities of a favorable clinical
outcome (mRS ≤ 1) after receiving thrombolysis or placebo, respectively54. The
remaining term PT, M|P is the expected counterfactual probability of a favorable
clinical outcome for the thrombolysis group if the distribution of the mediator had
been fixed to what it would have been under the placebo condition. The proportion
jointly mediated through all mediators included in a model was quantified as the
ratio log(NIE)/log(TE). All counterfactual probabilities were estimated using the
inverse probability weighting approach, employing simple logistic regressions as
exposure and outcome models. Weighting is a flexible approach to mediation
applicable in the context of non-rare binary outcomes which allows for causal
relations between different mediators and does not require estimation of separate
regression models for each of the mediators55.
A prerequisite for mediation to occur is that the exposure affects the mediator
and the mediator affects the outcome56. We therefore included regions as
mediators in the model 5-b based on the strength of association between treatment
allocation and local connectivity decline, and local connectivity decline and
functional outcome, varying the threshold for both criteria independently.
Mediation models were assessed statistically using the simple bootstrap with k=
10,000 resamples. Uncertainty in estimated natural indirect effects and proportions
mediated is reported as bias-corrected 95% confidence intervals. To prevent type I
error inflation in the context of assessing more than one mediation model we chose to
control the false discovery rate at 5%. Since we expected models with different, but
overlapping sets of mediating brain regions to exhibit a high degree of statistical
dependence, we used bootstrap samples to construct a sequence of rejection
thresholds in a step-down procedure that takes into account the joint distribution of
natural effects across models57. Uncertainty in the rejection thresholds was assessed
by bootstrapping the bootstrapped NIE estimates (k= 100 resamples).
In the multiple mediation model (5-b), the natural indirect effect of thrombolysis
mediated through prevented loss of connectivity, but not through prevented infarct
growth, cannot be statistically identified58. We therefore compared models (5-a) and
(5-b) using the same bootstrap approach as above and derived 95% confidence
intervals for the difference between the natural indirect effect mediated jointly
through prevented infarct growth and preserved connectivity on the one hand and
prevented infarct growth alone on the other hand.
Finally, we investigated whether any mediation effect of preserved local
connectivity would be specific to the alteplase-responsive clinically eloquent
regions identified above. We thus sampled uniformly k= 10,000 sets of brain
regions, estimated the corresponding mediation model (Fig. 5b) and constructed a
null distribution of natural indirect effects. We also repeated all mediation analyses
using the imputation-based approach implemented in the R package medflex v.0.6-
6, which confirmed our results59–61.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
All patient-level data used in the analysis, including age, baseline NIHSS score, lesion
volumes, treatment allocation, connectivity measurements, and functional outcome, are
available on GitHub (https://github.com/csi-hamburg/WAKE-UP-preserved-SC).
Imaging data, after de-identification, will be shared with the Virtual International Stroke
Trials Archive (VISTA) and be accessible according to the VISTA rules (http://www.
virtualtrialsarchives.org/vista).
Code availability
Code for all analyses presented in the paper and for the creation of figures is available on
GitHub (https://github.com/csi-hamburg/WAKE-UP-preserved-SC).
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